Immatics GAAP EPS of Euro0.14 beats, revenue of $161.9M
Source: SeekingAlpha
2025-03-27 08:33:01 ET
More on Immatics
- Immatics N.V.: Considering More Engineered T Cells For Cancer
- Seeking Alpha’s Quant Rating on Immatics
- Historical earnings data for Immatics
- Financial information for Immatics
Read the full article on Seeking Alpha
For further details see:
Immatics GAAP EPS of €0.14 beats, revenue of $161.9M
Immatics N.V.
NASDAQ: IMTX
IMTX Trading
-0.61% G/L:
$11.37 Last:
87,110 Volume:
$11.48 Open:
IMTX Latest News
May 12, 2026 07:00:00 am
Immatics Announces First Quarter 2026 Financial Results and Business Update
April 21, 2026 10:25:55 am
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
IMTX Stock Data
$1,341,978,928
63,814,383
N/A
32
N/A
Biotechnology & Life Sciences
Healthcare
DE
Tbingen
